Hemostemix Inc (HEM)

Hemostemix Leadership Attending Abundance360 SummitMarch 9, 2026 11:23 AM
NewsfileCalgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week.Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential technologies expected to reshape human health. At this event, Hemostemix Inc. is describing ACP-01 (VesCell), as a regenerative treatment designed to increase health span via microvascular circulation, as it drives the growth of new blood vessels where the body signals that need. Improved tissue perfusion and vascular regeneration are increasingly recognized as fundamental drivers of healthy aging. ACP-01's ability to restore circulation has been detailed in 11 peer-reviewed publications studying patients with conditions including angina, ischemic cardiomyopathy (ICM), dilated cardiomyopathy (DCM), and chronic limb-threatening ischemia (CLTI).Mr. Smeenk and Mr. Lacey will meet with investors and longevity participants to discuss the opportunity to join Hemostemix as shareholders in its commercialization stage in Florida and The Bahamas. "Abundance360 is an incredible event," said Thomas Smeenk, President and CEO of Hemostemix. "76% and 15% of Fountain Life members were found to have stage 1, or stage 2-3 coronary artery disease, respectively, after going trough the Fountain Life examinations. Peter Diamandis' motto 'do not die from something stupid' is obvious. The conversations about commercialization in Florida and The Bahamas are generating significant interest, as it is based on 498 treatments, seven clinical trials, and statistically significant improvement in heart function and circulation, which is the key to longevity," Smeenk said.ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com. For further information, please contact: Thomas Smeenk, President, CEO EM:?

🚨 Milestone: Hemostemix 🇨🇦 $HEM 📷 $HMTXF $2VF0 files FDA Pre-IND 1517 for ACP-01 (VesCell™) basket protocol.

One trial. Multiple billion-$ markets: PAD, CLI, angina, CHF, vascular dementia.

CHECK OUT THE FULL STORY: https://newsonwallstreet.com/hemostemix-files-pre%e2%80%91ind-fda-submission-for-a-basket-trial-why-it-matters-for-traders/

Hemostemix Files Pre-IND Basket Trial with FDA ! 😁

Key takeaway for $HEM longs: Pre-IND = still early, but FDA engagement is a green flag. Basket trial strategy expands potential indications. Market loves asymmetric setups like this if financing is managed

CHECK OUT THIS -- $HEM 🚀 Clinical data looks 🔥 $HEM $HMTXF

🚨 Massive market, proven trials, and a pipeline built on your own cells. Future of regen med?

Clinical-stage, Phase-II results, massive market. $HEM could be a biotech dark horse. 🚀 pic.twitter.com/LzztFs4i3j— Marina Dávila (@davilastocks) September 18, 2025

$HEM Hemostemix: Turning breakthrough science into investor opportunity🧬📈

$SAPX $TSLA $RNVA $XRPUSD $FMCC $NBRI $GRLF $FNMA $BIEL $CGAC $PSRU $TWOH $DBMM $DTREF $LWLG $NWBO $AVXL

$HEM Hemostemix: Turning breakthrough science into investor opportunity🧬📈$SAPX $TSLA $RNVA $XRPUSD $FMCC $NBRI $GRLF $FNMA $BIEL $CGAC $PSRU $TWOH $DBMM $DTREF $LWLG $NWBO $AVXL pic.twitter.com/JWIw9X652t— Marina Dávila (@davilastocks) September 1, 2025

Stem cell therapy is not "coming soon" — it’s happening now.
Innovation in healthcare isn’t optional — it’s essential. $HEM $HMTXF

🚨 Florida rollout milestone!

Hemostemix 🇨🇦 $HEM 🇺🇸 $HMTXF is live Friday with updates:

✅ Florida boots-on-the-ground.
✅ Patient testimonials.
✅ Investor milestones.

📅 Aug 29 | 12 PM ET
🔗 Register: https://bit.ly/4oLM4Jw
#Biotech #StemCells #AI #InvestingRevolution

ALERT: Hemostemix Slides into the AI Era! 🤖🚀

Hemostemix is rolling out a full scale AI strategy to supercharge its stem cell therapy platform covering patient care, clinical research, and operations:

Highlights:

HIPAA-compliant precision medicine diagnostics: unifies patient data for smarter insights

Acurist.AI cognitive screening: tracks subtle memory changes pre/post VesCell™ treatment

24/7 AI chatbot + decision-support tools : boosts patient engagement and outcomes

Research acceleration & predictive analytics : AI forecasts treatment response and streamlines trial design

AI-driven trial matching : rapid patient recruitment to speed enrollment

Operational automation : HubSpot-integrated AI handles scheduling, billing, follow-ups—cutting admin costs by up to 20%

Smart resource allocation & secure data ecosystem: dynamic staffing, HIPAA-compliant cloud data, and proactive compliance monitoring.

READ THE FULL STORY: https://hemostemix.com/hemostemix-announces-its-ai-strategy/

Hemostemix Inc. pioneers regenerative therapies—invest now in biotech innovation at just $0.09 a share.

Volume is what I am watching for...🥳no need to let me know I am watching...thanks...

Volume will move it up so watch for a big pop. Let you know when i do a big buy and you can jump in on at .05?
Thanks
rod

There was no movement so I am out until I see it move...🥳

Have to ask how long and how invested are you in HMTXF if you don't mind?
Richard

Timing is everything!

HMTXF...089...🥳...OTC partnering with a NAZ company sounds promising to me...Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASDAQ: AIFF) ("Firefly"), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders.

Hemostemix and Firefly will study brain wave activity in up to 100 patients before and after treatment with ACP-01 at baseline, 3-months, and 6-months post-treatment (the "Phase 1").

https://www.otcmarkets.com/stock/HMTXF/news/Hemostemix-and-FireFly-Neurosciences-Brain-Network-Analytics-BNATM-Engage-to-Complete-Phase-1-Vascular-Dementia-Clinical?id=469780

Still following Hemostemix? I would be engaged for the short run up!
$1+

Looking like Hemostemix may be an emerging leader in the stem cell arena? Now the recent pr announced the lowest COGS cost of goods in the industry?
$1.+

Investors in $HEM are still waiting for any positive financial data to emerge, but so far, it's been a disappointing journey.

Boom boom time